UNSPSC 51413902: Altapizone

This classification denotes a vasodilating agent with the molecular formula C24H28N4O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier SW3OJS6TOD, chemically known as 4-phenyl-4-(1,4,5,6-tetrahydro-6-oxo-3-pyridazinyl)-1-piperidinepropionanilide but generally known as altapizone, which bears US NIH Compound Identifier 178135. European Medicines Agency schedules Altapizone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05376MIG.

UNSPSC 51413902 Altapizone, a Commodity code, encompasses emergency and acute-care medications—specifically advanced life support drugs and generic multi-source pharmaceuticals—that state and local health systems, fire rescue departments, and human services agencies procure for emergency medical services, hospital formularies, and managed pharmacy benefit programs. State and local governments are soliciting these medications through sealed competitive bids, requests for proposal, and cooperative purchasing vehicles, with vendors required to meet strict expiration-date warranties, OSHA compliance for safety data sheets, FDA manufacturing standards, and in some cases accessibility documentation. The issuing bodies include city purchasing departments (Tampa), state health and human services commissions (Texas HHS), and multistate cooperative purchasing alliances (Minnesota MMCAP serving state and local facilities across multiple states including Oregon). Recent opportunities show a mix of direct-supply procurement for emergency response operations and bulk pharmaceutical distribution through authorized wholesaler networks serving broader government health systems.

Geographic activity concentrates in Florida, Texas, and the Upper Midwest. The City of Tampa's Hillsborough County sealed-bid procurement for Advanced Life Support Medications (26P00188, response date April 8, 2026) sought four specific emergency drugs—Labetalol, Epinephrine, Adenosine, and Diltiazem—with a one-year contract term, estimated value $40,000, and a 5 percent SLBE bid discount available. The Minnesota MMCAP Request for Proposal (S1070000015802, response date March 26, 2026) established a two-year multistate contract for generic pharmaceuticals and OTC products distributed through three authorized wholesalers, with evaluations weighted heavily toward price competitiveness (75 percent) and requiring vendors to maintain relationships with at least two wholesalers and comply with cGMP and Drug Supply Chain Security Act certification. Texas HHS issued a preliminary Request for Information (HHS0017013, posted April 3, 2026) to gather vendor capabilities on direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager arrangements, signaling potential future formal solicitation for alternative pharmacy distribution models.